multiple indications (RA, AS, PsA, psoriasis, Crohn's, UC, JIA)
Rheumatology · 2020–2020
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Additional uptake drivers for biosimilar adalimumab across all indications for which Humira is PBS listed, including rheumatoid arthritis, ankylosing… | Dec 2020 | Not recommended | input received Colitis Australia |
Who spoke
Colitis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.